Journal News

MCP: Just drops of viper venom
pack a deadly punch

Laurel Oldach
August 01, 2018

A bite from a lancehead viper can be fatal. Species in the family, among the most dangerous snakes in Central and South America, have venom that can disrupt blood clotting and cause hemorrhage, strokes and kidney failure.

Researchers at Brazil’s largest producer of anti-venoms have done a structural analysis of glycans modifying venom proteins in several species of lancehead. The report offers insight into the solubility and stability of toxic proteins from venom and into how venoms from different species vary. Scientists are working to map glycan structures back onto the proteins they modify.

Wikimedia user Leandro Avelar
Researchers studying venom from Bothrops jararaca (pictured) and related vipers have done a structural analysis of glycoproteins in the venom that may give insight into toxic proteins’ solubility and stability.

Solange Serrano, a researcher at the Laboratory of Applied Toxicology at the Instituto Butantan in Sao Paulo, studies the protein toxins in lancehead venom. In a recent article in Molecular & Cellular Proteomics, scientists from Serrano’s laboratory, in collaboration with researchers at the University of New Hampshire, report on the sweet side of snake venom toxins.

The researchers looked at glycans, a group of sugar molecules attached in a complex chain, often with many branches, that can be attached to proteins. According to Serrano, most proteins in lancehead venom are modified with glycans, which can affect the proteins’ folding, stability and binding. But little is known about glycan structure in the venom.

Serrano’s graduate student Debora Andrade-Silva visited the laboratory of glycomics expert Vernon Reinhold in New Hampshire to learn techniques for structural characterization of glycans. While there, Andrade-Silva and colleagues characterized the structure of 60 glycan chains in eight lancehead, or Bothrops, species’ venoms. The researchers isolated the glycans and analyzed them by mass spectrometry, breaking down each complex molecule into smaller, simpler ions. By piecing together the spectra of many such ions, they could tell which sugars were present and how they were linked into treelike glycan structures.

Lancehead venom contains nearly 100 milligrams of protein per milliliter of liquid. At this concentration, protein solutions tend to become viscous or form gels. Analyzing the structures of glycans attached to the proteins, the researchers found that a disproportionate number were tipped with sialic acid, a sugar with a negative charge.

“Glycans containing sialic acid may help in venom solubility and increase toxin half-life,” Serrano said.

Sialic acid on a toxic enzyme may also bind to host proteins called siglecs, pulling the enzyme closer to target cells for greater effect; this has been observed in other types of venom.

While Serrano’s group researches venom composition, the applications are close to home. Another department of the Instituto Butantan produces most of the anti-venom available in Brazil. Serrano said she hopes that basic research into venom toxins will help researchers develop improved treatments for envenomation.

“The antivenoms do a reasonable job, but they are not so good at neutralizing the local effects of snakebite,” Serrano said.

These effects, including swelling, hemorrhage and necrosis, can be so severe that doctors must sometimes amputate bitten limbs. Better understanding of how venom differs between snake species could improve the efficacy of anti-venom treatment.

Andrade-Silva and Serrano are working to map the structures from the glycan inventory back onto the proteins they modify. Because some venom proteins have been repurposed as medicines, knowing more about how glycosylation helps each protein fold, hold its shape and attach to binding partners may have applications in biotechnology.

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Stopping the devil in the dust
Feature

Stopping the devil in the dust

April 07, 2020

As clinicians, veterinarians and research scientists close in on potential vaccines for the devastating fungal illness Valley fever, the largest barrier likely remains outside the lab.

Life's little oscillations
News

Life's little oscillations

April 05, 2020

Concentrations of molecules rise and fall, genes switch on and off, and circadian clocks keep time. These biochemical fluctuations are crucial for myriad biological needs, and cells couldn't function without them.

A small trial finds that hydroxychloroquine is not effective for treating coronavirus
News

A small trial finds that hydroxychloroquine is not effective for treating coronavirus

April 05, 2020

Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney
Journal News

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney

April 03, 2020

In the inaugural JBC Methods Madness Tournament, cryo­–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% —​ a margin thinner than shaved ice. 

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.